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Abstract
Concurrent hematologic malignancies are relatively rare. We encountered a case of concurrent acute myeloid leukemia
(AML) and T lymphoblastic lymphoma. The bone marrow chromosome analysis showed the karyotype 46, XY, t(5;12)
(q33;p13), which indicated presence of PDGFRB gene translocations. Therefore, this disease belongs to the new WHO
category of myeloid and lymphoid neoplasms with abnormalities in PDGFRA, PDGFRB and FGFR1 genes. Although such
genetic mutations are prone to multi-lineage differentiation, the present case is in fact the first report of concurrent AML
and T lymphoblastic lymphoma involving PDGFRB mutations. The patient was treated with cytarabine and daunomycin
in combination with high dose dexamethasone. Allogeneic stem cell transplantation was performed after successful
remission induction for both entities. The patient eventually died of chronic graft-versus-host-disease related infection.
Based on such an experience, we suggest the decision of stem cell transplantation should be weighed carefully against
the risks, especially when tyrosine kinase inhibitors are safe and potentially effective in dealing with such entities.
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Background
In 2008, a new class of hematopoietic system disorders,
myeloid and lymphoid neoplasms with eosinophilia and
abnormalities in PDGFRA, PDGFRB and FGFR1 genes,
was created by WHO [1]. Although most cases presented
with myeloproliferative neoplasm (MPN) and eosinophilia,
this group of diseases was known to develop into multiple
lineages of hematologic malignancies both in animal mod-
els and human cases [2]. In humans, concurrent myeloid
neoplasms and T lymphoblastic lymphoma have been
reported with FIP1L1-PDGFRA fusion genes [3,4] but not
with any PDGFRB rearranged genes. Neoplastic ells bear-
ing such mutations are susceptible to tyrosine kinase inhi-
bitors and successful treatment experiences have been
reported [5-9].
Case presentation
A 41-year-old businessman presented with multiple sub-
cutaneous nodules in the arms and trunk 3 weeks before
admission. These nodules were rapidly enlarging but
neither painful nor pruritic. He also reported several sys-
temic symptoms including malaise, drenching night
s w e a ta n dg e n e r a l i z e da r t hralgia. His urine amount
decreased markedly and he gained 3 kilograms before
admission. At admission, subcutaneous nodules were
found in his arms, trunk and thighs. Enlarged lymph
nodes that were fixed, discrete and elastic were palpated
in neck, axillary, and inguinal areas. Liver and spleen
were not palpable. Marked general edema was observed.
Other physical findings were unremarkable. A complete
blood count revealed a hemoglobin level 10.9 g/L, a pla-
telet count 53 × 10
9/L, a white cell count 70.7 × 10
9/L
with 20% blasts, 3% promyelocytes, 7.5% myelocytes, 3%
metamyelocytes, 31% neutrophils, 0.5% eosinopils, 24.3%
monocytes and 10.8% lymphocytes. The liver biochemis-
try profiles were normal but the renal function tests
showed creatinine 2.21 mg/dL, uric acid 15.5 mg/dL, lac-
tate dehydrogenase 612 U/L, calcium 9.1 mg/dL, and
phosphate 2.4 mg/dL. Under the impression of sponta-
neous tumor lysis syndrome, he was treated with hydra-
tion and rasburicase 0.15 mg/kilogram. His renal
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biopsy of the right inguinal lymph node was done. The
sections showed fragments of lymphoid tissue with dif-
fuse infiltrates of medium-s i z e dl y m p h o i dc e l l s ,w h i c h
had fine chromatin and small nucleoli (Figure 1A). The
tumor cells were positive for CD3 (Figure 1B), CD5 and
TIA-1. A part of them were also positive for TdT (Figure
1C). They were negative for CD20, cyclin D1, myeloper-
oxidase (Figure 1D), CD4, CD8, CD30, CD56 and CD25.
About 95% of the tumor cells were positive Ki-67. It was
classified as T lymphoblastic lymphoma.
The bone marrow aspiration smear and biopsy revealed
hypercellular bone marrow with myeloblasts accounting
for 36.7% of nucleated cells (Figure 2A). All leukemic
cells were positive for peroxidase (Figure 2B). A flow
cytometric analysis revealed the leukemic cells were posi-
tive for CD13, CD33, CD14, CD15, CD65 and negative
for CD34, CD117, CD56, CD7 and CD19. In addition,
the immunohistochemical stain of the bone marrow
tissue section showed the blast cells were strongly posi-
tive for myeloperoxidase but negative for TdT, CD10,
CD2, CD5 and CD20. The diagnosis of AML was estab-
lished. The chromosome analysis revealed the karyotype
46, XY, t(5;12)(q33;p13). There was no detectable AML1-
ETO, CBFb-MYH11,o rMLL-PTD fusion transcripts
shown by reverse transcriptase polymerase chain reac-
tions. A fluorescent in situ hybridization (FISH) analysis
with dual color PDGFRB probes was performed on
patient’s BM sample. It was positive for PDGFRB
translocations.
He received induction chemotherapy with cytarabine
(100 mg/m
2/day continuous infusion for 7 days) and
daunomycin (50/m
2/day for 3 days). Dexamethasone
20 mg/day in divided doses was given in the same time,
tapered off in a month. He had complete regression of
lymph nodes and skin lesions and complete remission of
AML. He subsequently received 2 cycles of postremis-
sion chemotherapy (cycle 1: cytarabine 3 g/m
2 for
Figure 1 Histology of the lymph node biopsy. A. diffuse infiltrates of medium - s i z e dl y m p h o i dc e l l s ,w h i c hhad fine chromatin and small
nucleoli. B. tumor cells positive for CD3(Polyclonal). C.a part of tumor cells positive for TdT. D. tumor cells were negative for myeloperoxidase
(Polyclonal).
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2 for 6 doses and eto-
poside 100 mg/m
2/day for 3 days). In the state of con-
tinued remission, he underwent allogeneic stem cell
transplantation from an HLA-matched sibling donor.
Eleven months after transplantation, he died of chronic
graft versus host disease (GVHD) and related pulmonary
infection.
Discussion
Concurrent myeloid and lymphoid malignancies are quite
uncommon. The difficulty of diagnosis can be illustrated
in the present case. At presentation, generalized subcuta-
neous tumors and lymphadenopathies led to the diagnosis
of a high grade lymphoma. The pathological diagnosis of
T lymphoblastic lymphoma was made unequivocally by
typical morphology and detailed immunophenotypical stu-
dies. The clinical course was complicated with sponta-
neous tumor lysis syndrome, which typically occurred in
high grade lymphoma and therefore supported the diagno-
sis of T lymphoblastic lymphoma. Although lymphoblastic
lymphoma may involve bone marrow or peripheral blood,
the results of bone marrow studies revealed the leukemic
cells did not belong to the T-lineage. The strongly positive
myeloperoxidase staining suggested the diagnosis of AML.
This was further confirmed definitively by its typical
immunophenotypical profile. Some leukemic cells of AML
may occasionally express T cell markers. In our case, how-
ever, the leukemia cells was found negative for CD2, CD5
and CD7, making aberrant expression of AML relatively
unlikely. The diagnosis of concomitant AML and T lym-
phoblastic lymphoma, was confirmed.
Although it appears unusual, such concurrence is not
coincidental. In English literature, similar cases have been
reported. In 2007, Metzgerot et al. reported 7 cases of
AML or T lymphoblastic lymphoma bearing FIP1L1-
PDGFA fusion genes. In 2 cases, T lymphoblastic lym-
phoma was found synchronously with myeloid neoplasms
(acute eosinophilic leukemia in one and MPN in the
other) [4]. In 2008, Capovilla et al. reported another case
of synchronous chronic eosinophilic leukemia and T
lymphoblastic lymphoma. Like the previous report, the
leukemic cells were found to bear FIP1L1-PDGFRA fusion
genes [3]. It appears from these reports that such genetic
aberrations may lead to mixed lineage differentiation. In
contrast to the previous reports with PDGFRA gene rear-
rangements, the present case was found to bear t(5;12)
(q33;p13). This translocation most likely involves PDGFRB
genes mapped on chromosome 5p. This assumption was
further confirmed by studies of FISH. Based on chromoso-
mal mapping and prior literature reports, the most likely
partner gene is ETV6 [10].
In 2008 WHO classification, a new class of hemato-
poietic diseases, myeloid and lymphoid neoplasms with
eosinophilia and abnormalities in PDGFRA, PDGFRB and
FGFR1 genes, were introduced [1]. In such a classifica-
tion system, all cases of concurrent myeloid neoplasms
and T lymphomblastic lymphoma, including the present
case, belong to the same category. While most cases of
this entity presented with MPNs, the genetic aberrations
have a wide spectrum of differentiations, including eosi-
nophilia, myelodysplastic syndrome, chronic myelomo-
nocytic leukemia, AML, B or T cell acute lymphoblastic
leukemia, T lymphoblastic lymphoma, and disorders with
mast cell proliferation [2]. Most cases with PDGFRA
gene rearrangements manifest as MPNs, usually chronic
eosinophilic leukemia. PDGFRB gene rearrangement
cases typically present as MPNs which are almost always
accompanied with eosinophilia. Aberrations of FGFR1
genes are also commonly associated with MPNs with
eosinophilia. In particular, this genetic mutation is often
associated with differentiation into both myeloid and
lymphoid lineages. The most common lymphoid neo-
plasm is T lymphoblastic lymphoma. The concurrence of
myeloid and lymphoid malignancies was reported both in
human cases and animal models [2].
While these reports revealed it is not uncommon for
PDGFRA and FGFR1 genetically rearranged cells to differ-
entiate into lymphoid neoplasms, hematologic diseases
bearing PDGFRB mutations are rare [2,5]. The two largest
series reported in literature included 22 and 9 cases
Figure 2 Bone marrow aspiration smear. A. myeloblasts accounting for 36.7% of nucleated cells. B. all leukemic cells positive for peroxidase.
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develop into B and T lineage lymphoma [2]. This differen-
tiation pattern was well described in transgenic mice mod-
els [11,12]. However, according to an extensive review by
Holroyd et al, patients with PDGFRB mutations have not
been known to develop lymphoid malignancies. This is
somewhat surprising and may be explained by the rarity of
such mutations among humans [2]. As a result, the case in
the present article is the first case report of lymphoma and
concurrent AML bearing PDGFRB gene mutations.
Treatment of concurrent AML and T lymphoblastic
lymphoma and AML is a clinical challenge. There is
mounting evidence that PDGFRA, PDGFRB and FGFR1
entities respond well to tyro s i n ek i n a s ei n h i b i t o r s
[2,5,9,10,13]. However, tyrosine kinase inhibitors are
expensive and still off-label for lymphoma. Therefore, we
did not consider tyrosine kinase inhibitors as the frontline
treatment in this case. In view of the simultaneous expres-
sion of myeloid and lymphoid lineage features, considera-
tion of chemotherapeutic regimens is similar to that of bi-
phenotypic leukemia. Bi-phenotypic leukemia is an
uncommon disorder. No consensus protocol is available
for treatment. Some studies suggest that bi-phenotypic
leukemia has good responses to treatment directed against
AML [14-16]. As a result, we chose treatment that was
based on cytarabine and daunomycin. Steroids were
included in the induction phase and complete remission
was achieved for both AML and lymphoma. The patient
subsequently underwent sibling-matched, allogeneic stem
cell transplantation, which was quite successful until the
development of chronic GVHD. Although the patient died
of GVHD and related infections, he remained free from
both malignancies for at least 11 months after transplanta-
tion. We believe allogeneic stem cell transplantation is an
effective, albeit risky treatment option. Clinicians should
weigh the risk against potential benefits before deciding
treatment strategies, especially when tyrosine kinase inhi-
bitors have become relatively safe and effective options.
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